Terms: = Ovarian cancer AND HIF1A, Q16665, 3091, ENSG00000100644, MOP1, HIF1-ALPHA, PASD8, HIF-1alpha AND Prognosis
39 results:
1. cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
Feng S; Ding B; Dai Z; Yin H; Ding Y; Liu S; Zhang K; Lin H; Xiao Z; Shen Y
J Transl Med; 2024 Mar; 22(1):280. PubMed ID: 38491511
[TBL] [Abstract] [Full Text] [Related]
2. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract] [Full Text] [Related]
3. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
4. β-catenin/TCF4-induced SCUBE3 upregulation promotes ovarian cancer development via HIF-1 signaling pathway.
Shen J; Ma X; Wei Z; Qian Q; Jing A; Ding Y; Geng T; Qin J; Ma L; Chen Y; Ji J; Liu B; Huang J
Mol Cell Endocrinol; 2024 Mar; 582():112127. PubMed ID: 38109990
[TBL] [Abstract] [Full Text] [Related]
5. Lysine demethylase 3A in hypoxic macrophages promotes ovarian cancer development through regulation of the vascular endothelial growth factor A/Akt signaling.
Song Y; Li L; Xi Y
Tissue Cell; 2023 Dec; 85():102253. PubMed ID: 37890327
[TBL] [Abstract] [Full Text] [Related]
6. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
[TBL] [Abstract] [Full Text] [Related]
7. A Multistep Tumor Growth Model of High-Grade Serous ovarian Carcinoma Identifies Hypoxia-Associated Signatures.
More MH; Varankar SS; Naik RR; Dhake RD; Ray P; Bankar RM; Mali AM; Subbalakshmi AR; Chakraborty P; Jolly MK; Bapat SA
Cells Tissues Organs; 2024; 213(2):79-95. PubMed ID: 35970135
[TBL] [Abstract] [Full Text] [Related]
8. CRMP2 derived from cancer associated fibroblasts facilitates progression of ovarian cancer via HIF-1α-glycolysis signaling pathway.
Jin Y; Bian S; Wang H; Mo J; Fei H; Li L; Chen T; Jiang H
Cell Death Dis; 2022 Aug; 13(8):675. PubMed ID: 35927239
[TBL] [Abstract] [Full Text] [Related]
9. Understanding the Correlation between Metabolic Regulator SIRT1 and Exosomes with CA-125 in ovarian cancer: A Clinicopathological Study.
Roy S; Das A; Vernekar M; Mandal S; Chatterjee N
Biomed Res Int; 2022; 2022():5346091. PubMed ID: 35496046
[TBL] [Abstract] [Full Text] [Related]
10. TLR4 Agonist and Hypoxia Synergistically Promote the Formation of TLR4/NF-
Zhao B; Niu X; Huang S; Yang J; Wei Y; Wang X; Wang J; Wang Y; Guo X
Anal Cell Pathol (Amst); 2022; 2022():4201262. PubMed ID: 35464826
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and clinicopathological implications of expression of Beclin-1 and hypoxia-inducible factor 1α in serous ovarian carcinoma: an immunohistochemical study.
Alabiad M; Harb O; Mandour D; Hemeda R; Z Ahmed R; El-Taher A; Osman G; Shalaby A; A A Alnemr A; T Abdelfattah M
Pol J Pathol; 2021; 72(1):23-38. PubMed ID: 34060285
[TBL] [Abstract] [Full Text] [Related]
12. Up-regulation of HDAC6 Results in Poor prognosis and Chemoresistance in Patients With Advanced ovarian High-grade Serous Carcinoma.
Yano M; Miyazawa M; Ogane N; Ogasawara A; Hasegawa K; Narahara H; Yasuda M
Anticancer Res; 2021 Mar; 41(3):1647-1654. PubMed ID: 33788761
[TBL] [Abstract] [Full Text] [Related]
13. Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions.
Martí JM; Garcia-Diaz A; Delgado-Bellido D; O'Valle F; González-Flores A; Carlevaris O; Rodríguez-Vargas JM; Amé JC; Dantzer F; King GL; Dziedzic K; Berra E; de Álava E; Amaral AT; Hammond EM; Oliver FJ
Redox Biol; 2021 May; 41():101885. PubMed ID: 33581682
[TBL] [Abstract] [Full Text] [Related]
14. Hypoxia-inducible Factor-1α Suppression in ovarian Clear-cell Carcinoma Cells by Silibinin Administration.
Miyazawa M; Yasuda M; Miyazawa M; Ogane N; Katoh T; Yano M; Hirasawa T; Mikami M; Ishimoto H
Anticancer Res; 2020 Dec; 40(12):6791-6798. PubMed ID: 33288572
[TBL] [Abstract] [Full Text] [Related]
15. MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.
Sun C; Li X; Guo E; Li N; Zhou B; Lu H; Huang J; Xia M; Shan W; Wang B; Li K; Weng D; Xu X; Gao Q; Wang S; Hu J; Lu Y; Mills GB; Chen G
Oncogene; 2020 Feb; 39(8):1681-1695. PubMed ID: 31705064
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies.
Yu M; Chen S; Hong W; Gu Y; Huang B; Lin Y; Zhou Y; Jin H; Deng Y; Tu L; Hou B; Jian Z
J Cancer Res Clin Oncol; 2019 Apr; 145(4):967-999. PubMed ID: 30825027
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Yano M; Katoh T; Miyazawa M; Miyazawa M; Ogane N; Miwa M; Hasegawa K; Narahara H; Yasuda M
Sci Rep; 2019 Feb; 9(1):2397. PubMed ID: 30787326
[TBL] [Abstract] [Full Text] [Related]
18. Association of the hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms with prognosis in ovarian clear cell carcinoma.
Suzuki H; Yano M; Miyazawa M; Miyazawa M; Ogane N; Hasegawa K; Tsuda H; Yoshida M; Okagaki R; Ishihara O; Yasuda M
J Ovarian Res; 2019 Jan; 12(1):7. PubMed ID: 30678691
[TBL] [Abstract] [Full Text] [Related]
19. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract] [Full Text] [Related]
20. AEG-1 Contributes to Metastasis in Hypoxia-Related ovarian cancer by Modulating the hif-1alpha/NF-kappaB/VEGF Pathway.
Yu X; Wang Y; Qiu H; Song H; Feng D; Jiang Y; Deng S; Meng H; Geng J
Biomed Res Int; 2018; 2018():3145689. PubMed ID: 29770329
[TBL] [Abstract] [Full Text] [Related]
[Next]
